Analysen von Michael Leuchten
| 28.10.22 | Sanofi Neutral | UBS AG | |
| 27.10.22 | Bayer Buy | UBS AG | |
| 25.10.22 | Novartis Neutral | UBS AG | |
| 24.10.22 | Sartorius vz. Buy | UBS AG | |
| 21.10.22 | GSK Neutral | UBS AG | |
| 19.10.22 | Sartorius vz. Buy | UBS AG | |
| 18.10.22 | Roche Neutral | UBS AG | |
| 17.10.22 | Bayer Buy | UBS AG | |
|
Werbung
|
|||
| 13.10.22 | GSK Neutral | UBS AG | |
| 10.10.22 | Shell (ex Royal Dutch Shell) Buy | UBS AG | |
| 10.10.22 | Bayer Buy | UBS AG | |
| 29.09.22 | Roche Neutral | UBS AG | |
| 26.09.22 | Novartis Neutral | UBS AG | |
| 26.09.22 | Sartorius vz. Buy | UBS AG | |
| 29.08.22 | Bayer Buy | UBS AG | |
| 25.08.22 | Novartis Neutral | UBS AG | |
| 23.08.22 | Novo Nordisk Sell | UBS AG | |
| 17.08.22 | Novo Nordisk Sell | UBS AG | |
| 04.08.22 | Merck Neutral | UBS AG | |
| 04.08.22 | Bayer Buy | UBS AG | |
| 01.08.22 | Bayer Buy | UBS AG | |
| 27.07.22 | Sartorius vz. Buy | UBS AG | |
| 21.07.22 | Roche Neutral | UBS AG | |
| 21.07.22 | Sartorius vz. Buy | UBS AG | |
| 11.07.22 | Roche Neutral | UBS AG | |
| 28.06.22 | Novo Nordisk Sell | UBS AG | |
| 24.06.22 | Novo Nordisk Neutral | UBS AG | |
| 22.06.22 | Bayer Buy | UBS AG | |
| 14.06.22 | AstraZeneca Neutral | UBS AG | |
| 19.05.22 | Bayer Buy | UBS AG | |
| 16.05.22 | Sartorius vz. Buy | UBS AG | |
| 12.05.22 | Merck Neutral | UBS AG | |
| 11.05.22 | Bayer Buy | UBS AG | |
| 11.05.22 | Roche Sell | UBS AG | |
| 10.05.22 | Bayer Buy | UBS AG | |
| 25.04.22 | Roche Sell | UBS AG | |
| 21.04.22 | Sartorius vz. Neutral | UBS AG | |
| 19.04.22 | Roche Sell | UBS AG | |
| 08.04.22 | Sartorius vz. Neutral | UBS AG | |
| 04.04.22 | Bayer Buy | UBS AG | |
| 17.03.22 | Bayer Buy | UBS AG | |
| 10.03.22 | Bayer Buy | UBS AG | |
| 07.03.22 | AstraZeneca Buy | UBS AG | |
| 04.03.22 | Merck Neutral | UBS AG | |
| 01.03.22 | Bayer Buy | UBS AG | |
| 28.02.22 | Sartorius vz. Sell | UBS AG | |
| 28.02.22 | Merck Neutral | UBS AG | |
| 23.02.22 | Fresenius Medical Care (FMC) St. Buy | UBS AG | |
| 22.02.22 | Fresenius Neutral | UBS AG | |
| 18.02.22 | AstraZeneca Buy | UBS AG | |